Significant efforts have been devoted to the development of nanoparticular delivering systems targeting tumors. However, clinical applications of nanoparticles is hampered by insufficient size homogeneity, difficulties in reproducible synthesis and manufacturing, frequent high uptake in the liver, systemic toxicity of the carriers (particularly for inorganic nanoparticles) and insufficient selectivity for tumor cells. We have recently discovered the ability of properly modified transmembrane peptides to assemble into remarkably uniform spherical nanoparticles with innate biological activity. Self-assembly is driven by a structural transition of the peptide that adopts predominantly a beta-hairpin conformation in aqueous solutions, but folds into an alpha-helix upon spontaneous fusion with cell membrane. Alpha-helical peptide interferes with proper assembly of the target receptor and inhibits its function. The best characterized antagonist inhibits signaling through CXCR4 inhibitor with IC50=100 nM. Addition of polyethylene glycol (PEG) chains of up to 27 monomeric units stabilizes nanoparticles and prevents their superaggregation without interfering with biological activity. Longer PEG chains diminish efficient fusion of nanoparticles with the cell membrane and reduce anti-receptor activity. Nanoparticles efficiently encapsulate poorly soluble hydrophobic drugs, thus providing a unique delivery system with dual anti-tumor activity. Even empty nanoparticles effectively inhibit lung metastasis in a mouse model of human breast tumor, due to their ability to inhibit CXCR4 receptor signaling. We are now in the process of development nanoparticles that fuse with cells in receptor-mediated manner, similar to viruses. Conjugates of self-assebling peptide to ligands of receptors overexpressed on prostate tumors resulted in nanoparticles that fuse more effectively with cells expressing corresponding receptor. Self-assembling virus-like particles with intrinsic biological activity present a new paradigm in anti-cancer drug development. We have now generated fully synthetic self-assembling nanoparticles that fuse with cells in receptor-mediated manner, like natural viruses. Synthetic particles were designed to fuse with cells through three receptors over expressed on prostate tumor cells: gastrin-releasing peptide receptor, leutenizing hormone releasing peptide receptor and prostate-specific membrane antigene. All three synthetic virus-like particles have been shown to fuse with cells very selectively: blocking the corresponding receptor with its ligand completely prevents cell fusion.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Grozdanovic, Milica; Laffey, Kimberly G; Abdelkarim, Hazem et al. (2018) Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness. J Allergy Clin Immunol :
Evans, Ann E; Tripathi, Abhishek; LaPorte, Heather M et al. (2016) New Insights into Mechanisms and Functions of Chemokine (C-X-C Motif) Receptor 4 Heteromerization in Vascular Smooth Muscle. Int J Mol Sci 17:
Tripathi, Abhishek; Vana, P Geoff; Chavan, Tanmay S et al. (2015) Heteromerization of chemokine (C-X-C motif) receptor 4 with ?1A/B-adrenergic receptors controls ?1-adrenergic receptor function. Proc Natl Acad Sci U S A 112:E1659-68
Lee, Youngshim; Chen, Yuhong; Tarasova, Nadya I et al. (2011) The structure of monomeric components of self-assembling CXCR4 antagonists determines the architecture of resulting nanostructures. Nanotechnology 22:505101
Tarasov, Sergey G; Gaponenko, Vadim; Howard, O M Zack et al. (2011) Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles. Proc Natl Acad Sci U S A 108:9798-803
Polgar, Orsolya; Ierano, Caterina; Tamaki, Akina et al. (2010) Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry 49:2235-45